Imipramine compliance in adolescents

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 39, Issue 3, 2000, Pages 284-291

  Bernstein, Gail A ^a   Anderson, Lesley K ^a   Hektner, Joel M ^a   Realmuto, George M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Compliance; Imipramine; Psychopharmacology

Indexed keywords

IMIPRAMINE; PLACEBO;

ACADEMIC ACHIEVEMENT; ADOLESCENT; ADULT; ANXIETY NEUROSIS; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FAMILY LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTHER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIST; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SCHOOL CHILD; SIDE EFFECT;

EID: 0034006117     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200003000-00009     Document Type: Article

References (45)

1. Achenbach TM (1991), Manual for the Child Behavior Checklist/4-18 and 1591 Profile. Burlington: University of Vermont Department of Psychiatry
2. Bartko G, Herczeg I, Zador G (1988), Clinical symptomatology and drug compliance in schizophrenia patients. Acta Psychiatr Scand 77:74-76
3. Bebbington PE (1995), The content and context of compliance. Int Clin Psychopharmacol 9(suppl 5):4l-50
4. Bernstein GA, Borchardt CM, Perwien AR et al. (2000), Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry 39:276-283
5. Bernstein GA, Crosby RD, Perwien AR, Borchardt CM (1996), Anxiety Rating for Children-Revised: reliability and validity. J Anxiety Disord 10:97-114
6. Biederman J, Faraone SV, Milberger S et al. (1996), Is childhood oppositional disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 35:1193-1204
7. Bobrow ES, AvRuskin TW, Siller J (1985), Mother-daughter interaction and adherence to diabetes regimens. Diabetes Care 8:146-151
8. Brown RT, Borden KA, Wynne ME, Spunt AL, Clingerman SR (1987), Compliance with pharmacological and cognitive treatments for attention deficit disorder. J Am Acad Child Adolesc Psychiatry 26:521-526
9. Bush PJ, Iannotti RJ (1988), Origins and stability of children's health beliefs relative to medicine use. Soc Sci Med 27:345-352
10. Creer TL (1991), The application of behavioral procedures to childhood asthma: current and future perspectives. Patient Educ Couns 17:9-22
11. Cromer BA, Tarnowski KJ (1989), Noncompliance in adolescents: a review. J Dev Behav Pediatr 10:207-215
12. Demyttenaere K (1997), Compliance during treatment with antidepressants. J Affect Disord 43:27-39
13. DePaola LM, Roberts MC, Blaiss MS, Frick PJ, McNeal RE (1997), Mothers' and children's perceptions of asthma medication. Child Health Care 26:265-283
14. Emslie GJ, Rush J, Weinberg WA et al. (1997), A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037
15. Firestonc P (1982), Factors associated with children's adherence to stimulant medication. Am J Orthopsychiatry 52:447-457
16. Friedman IM, Litt IF, King DR et al. (1986), Compliance with anticonvulsant therapy by epileptic youth: relationships to psychosocial aspects of adolescent development. J Adolesc Health Care 7:12-17
17. Gitlin MJ, Cochran SD, Jamison KR (1989), Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 50:127-131
18. Glassman AH, Perel JM (1973), The clinical pharmacology of imipramine: implications for therapeutics. Arch Gen Psychiatry 28:649-653
19. Gram LF (1988), Imipramine: a model substance in pharmacokinetic research. Acta Psychiatr Scand Suppl 345:81-84
20. Gudas LJ, Koocher GP, Wypij D (1991), Perceptions of medical compliance in children and adolescents with cystic fibrosis. J Dev Behav Pediatr 12:236-242
21. Guy W (1976), CGI Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology (DHEW Publication ADM 76-338). Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch
22. Haynes RB (1979a), Introduction. In: Compliance in Health Care, Haynes RB, Taylor DW, Sackett DL, eds. Baltimore: Johns Hopkins University Press, pp I-2
23. Haynes RB (1979b), Determinants of compliance: the disease and the mechanics of treatment. In: Compliance in Health Care, Haynes RB, Taylor DW, Sackett DL, eds. Baltimore: Johns Hopkins University Press, p 60
24. Haywood TW, Kravits HM, Grossman LS, Cavanaugh JL, Davis JM, Lewis DA (1995), Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 152:856-861
25. Jamison KR, Gerner RH, Goodwin FK (1979), Patient and physician attitudes toward lithium: relationship to compliance. Arch Gen Psychiatry 36:866-869
26. Kane JM (1986), Prevention and treatment of neuroleptic noncompliancc. Psychiatr Ann 16:576-579
27. Kaplan RM, Simon HJ (1990), Compliance in medical care: reconsideration of self-predictions. Ann Behav Med 12:66-71
28. Lloyd A, Horan W, Borgaro SR, Stokes JM, Pogge DL, Harvey PD (1998), Predictors of medication compliance after hospital discharge in adolescent psychiatric patients. J Child Adolesc Psychopharmacol 8:133-141
29. Marshall WA, Tanner JM (1969), Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291-303
30. Marshall WA, Tanner JM (1970), Variations in the pattern of pubertal changes in boys. Arch Dis Child 45:13-23
31. Morinobu S, Tanaka T, Kawakatsu S et al. (1997), Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci 51:253-257
32. Olson DH, Bell R, Portner J (1982), Family Adaptability and Cohesion Evaluation Scale II, Available from Life Innovations, Family Inventories Project, PO Box 190, Minneapolis, MN 55440-0190
33. Olson DH, McCubbin HI, Barnes H, Larsen A, Muxen M, Wilson M (1983), Families: What Makes Them Work. Beverly Hills, CA: Sage
34. Pande AC, Sayler ME (1993), Adverse events and treatment discontinuations in fluoxetine clinical trials, Int Clin Psychopharmacol 8:267-269
35. Poznanski EO, Freeman LN, Mokros HB (1985), Children's Depression Rating Scale-Revised. Psychopharmacol Bull 4:979-989
36. Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L, Gibbons R (1984), Preliminary studies of the reliability and validity of the Children's Depression Rating Scale. J Am Acad Child Psychiatry 23:191-197
37. Reich W, Weiner Z (1990), Diagnostic Interview for Children and Adolescents-Revised-Child Version and Diagnostic Interview for Children and AdolescentsRevised-Parent Version, St Louis: Washington University Division of Child Psychiatry
38. Reisby N, Gram LF, Bech P et al. (1977), Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology (Berl) 54:263-272
39. Riddle MA, Scahill L, King RA et al. (1992), Double-blind, crossover trial of fluoxetine and placebo in children and adolescents widi obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31:1062-1069
40. Sackett DL, Haynes RB, Tugwell P (1985), Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little Brown, pp 249-281
41. Shaffer D, Fisher P, Dulcan MK et al. (1996), The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA study. J Am Acad Child Adolesc Psychiatry 35:865-877
42. Silva RR, Muñoz DM, Daniel W, Barickman J, Friedhoff AJ (1996), Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. J Clin Psychiatry 57:129-135
43. Sleator EK (1985), Measurement of compliance. Psychopharmacol Bull 21:1089-1093
44. Smith CM, Barzman D, Pristach CA (1997), Effect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol 37:147-154
45. Stine JJ (1994), Psychosocial and psychodynamic issues affecting noncompliance with psychostimulant treatment. J Child Adolesc Psychopharmacol 4:75-86